Rhode Island Hospital
lifespan.orgTotal trials
185
Active
32
Phase 3
9
Total enrollment
44,969
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 10 of 10 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ropivacaine | — | — | — | — | 2 | ||
| Dexmedetomidine | — | — | — | — | — | 1 | |
| Botulinum toxin | — | — | — | — | — | 1 | |
| Standard-of-care corticosteroid injections | — | — | — | — | — | 1 | |
| Buprenorphine | — | — | — | — | — | 1 | |
| Treprostinil | — | — | — | — | — | 1 | |
| Vitamin A | — | — | — | — | — | 1 | |
| Nicotinamide | — | — | — | — | — | 1 | |
| Open-label Placebo | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2026-09-30
- 2027-01
- 2027-06
- 2027-08-01
- 2028-01-01
- 2028-06-30
Top conditions
- HIV Infections11
- HIV8
- Depression7
- Medication Adherence6
- Asthma5
- Opioid Use Disorder4
- Hiv4
- Sleep4
Frequently asked questions about Rhode Island Hospital
- How many clinical trials does Rhode Island Hospital have on ClinicalTrials.gov?
- Rhode Island Hospital is listed as the lead sponsor on 185 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Rhode Island Hospital's trials are in Phase 3?
- 9 of Rhode Island Hospital's trials are in Phase 3, spread across 10 active drug programs.
- What therapeutic areas does Rhode Island Hospital focus on?
- Rhode Island Hospital's most-studied conditions on ClinicalTrials.gov are HIV Infections, HIV, Depression, Medication Adherence, Asthma.
- When are Rhode Island Hospital's next clinical trial readouts?
- Rhode Island Hospital has 7 upcoming primary-completion readouts tracked here; the soonest is “Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis”, expected around 2025-12.